These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 12529671

  • 1. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E, Mazur J, Söderhäll S, Porwit-MacDonald A.
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [Abstract] [Full Text] [Related]

  • 2. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP, Cheng YF, Liu GL, Lu AD, Liu YR, Wang H.
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [Abstract] [Full Text] [Related]

  • 3. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
    Pawińska-Wasikowska K, Balwierz W.
    Przegl Lek; 2010 Jul; 67(6):361-5. PubMed ID: 21344762
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
    Cho YU, Park CJ, Cha CH, Chi HS, Jang S, Kim MJ, Lee KH, Lee JH, Lee JH, Seo JJ, Im HJ.
    Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
    [Abstract] [Full Text] [Related]

  • 6. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G, Yaniv I.
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [Abstract] [Full Text] [Related]

  • 7. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M, De Zen L, Sanzari MC, Maglia O, Dworzak MN, Ratei R, Biondi A, Basso G, Gaipa G, I-BFM-ALL-FCM-MRD-Study Group.
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [Abstract] [Full Text] [Related]

  • 8. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L, López O, Martino R, Brunet S, Bellido M, Rubiol E, Sierra J, Nomdedéu JF.
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [Abstract] [Full Text] [Related]

  • 9. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Jul; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 10. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T, Yokota S, Nakao M, Misawa S, Takaue Y, Koizumi S, Kawai S, Fujimoto T.
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [Abstract] [Full Text] [Related]

  • 11. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X, Zou Y, Wang H, Chen X, Ruan M, Chen Y, Yang W, Guo Y, Liu T, Zhang L, Wang S, Zhang J, Liu F, Cai X, Qi B, Chang L, Zhu X.
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [Abstract] [Full Text] [Related]

  • 12. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AE, van der Schoot CE.
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [Abstract] [Full Text] [Related]

  • 13. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J, Orfao A, Vidriales B, Macedo A, Martínez A, González M, López-Berges MC, Valverde B, San Miguel JF.
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN, Savva NN, Fedasenka UU, Romancova AS, Krasko OV, Eckert C, von Stackelberg A, Aleinikova OV.
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [Abstract] [Full Text] [Related]

  • 15. [Application of triple-color flow cytometry for minimal residual disease detection in acute B-lymphoblastic leukemia].
    Chen T, Zhu Y, Zhou X, Wang Y, Ying D.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jan; 22(1):20-3. PubMed ID: 11877045
    [Abstract] [Full Text] [Related]

  • 16. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A.
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment.
    Björklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S, Ahlberg AJ, Kauric G, Mäntymaa P, Osnes L, Penttilä TL, Marquart H, Savolainen ER, Siitonen S, Torikka K, Mazur J, Porwit A.
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):406-15. PubMed ID: 19648789
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.